Summary We assessed the cytotoxic interaction between paclitaxel and 5-fluorouracil administered at various schedules against four human carcinoma cell lines, A549, MCF7, PAI and WiDr. The cells were exposed simultaneously to paclitaxel and to 5-fluorouracil for 24 h or sequentially to one drug for 24 h followed by the other for 24 h, after which they were incubated in drug-free medium for 4 and 3 days respectively. In another experiment, the cells were exposed simultaneously to both agents for 5 days. Cell growth inhibition was determined by MTT reduction assay. The effects of drug combinations at IC80 were analysed by the isobologram. The cytotoxic interaction of paclitaxel and 5-fluorouracil was definitely schedule dependent. Simultaneous exposure to paclitaxel and 5-fluorouracil for 24 h showed mainly subadditive effects in A549, MCF7 and WiDr cell lines, whereas it showed additive effects in PAI cells. Sequential exposure to paclitaxel followed by 5-fluorouracil showed additive effects in all cell lines. Sequential exposure to 5-fluorouracil followed by paclitaxel showed subadditive effects in A549, MCF7 and PAl cells. Whereas it showed additive effects in WiDr cells. These findings suggest that maximum cytotoxic effects can be obtained when paclitaxel precedes 5-fluorouracil. Interestingly, the continuous (5-day) exposure to paclitaxel and 5-fluorouracil had additive effects in A549, PAl and WiDr cells, indicating that the prolonged simultaneous administration of these agents may circumvent the antagonistic interaction produced by short-term simultaneous administration. These findings may be useful in clinical trials of combination chemotherapy with paclitaxel and 5-fluorouracil.
Paclitaxel (taxol), a plant product isolated from the bark of the Pacific yew, Taxus brevifolia (Wani et al., 1971) , is a novel antimicrotubular agent that binds to the microtubules, promotes microtubule assembly and stabilises tubulin polymer formation (Schiff et al., 1979 (Schiff et al., , 1981 Kumar et al., 1981) . In clinical studies, the dose-limiting toxicity of paclitaxel was shown to be granulocytopenia; other toxic effects shown were hypersensitivity reaction, neuropathy, mucositis, slight nausea and vomiting, and slight cardiac injury (Grem et al., 1987; Donehower et al., 1987; Wiernilk et al., 1987) . Significant paclitaxel anti-tumour activity has been reported in patients with ovarian, breast, lung, head and neck, and oesophageal cancers (McGuire et al., 1989; Holms et al., 1991; Donehower et al., 1993; Ettinger et al., 1993; Murphy et al., 1993) . Its impressive clinical activity has prompted considerable interest in combining this drug with other anti-tumour agents. Clinical trials of its anti-tumour effects in combination with several other anti-tumour agents are now in progress.
For many years, 5-fluorouracil has been the mainstay of therapy for patients with solid tumours. 5-Fluorouracil, alone or in combination with other agents, is widely used in the treatment of gastrointestinal, breast and lung cancers-all non-curable diseases. It would be attractive to use paclitaxel and 5-fluorouracil in combination against these malignancies. As paclitaxel exerts its cytotoxic effects through a mechanism different from that of 5-fluorouracil, and it has no crossresistance with 5-fluorouracil (Gupta, 1983 ), it appears reasonable to attempt to use these drugs in combination. Clinical trials of the combination of paclitaxel and 5-fluorouracil in a variety of schedules have, indeed, been initiated (Elkordy et al., 1994; Klaassen et al., 1994; Madajewicz et al., 1995; Paul et al., 1995; Takimoto et al., 1995) . However, it has not been determined whether paclitaxel and 5-fluorouracil should be given concomitantly or sequentially, or what the optimal infusion durations of each drug are. It is important to identify the optimal schedule for this combination; hence, in the present study, we attempted to elucidate the cytotoxic effects of paclitaxel and 5-fluorouracil combinations administered at various schedules in four human carcinoma cell lines. (Mosmann, 1983) as described previously (Kano et al., 1991 Data analysis Dose-response curves were plotted on a semilog scale as a percentage of the control, the cell number of which was obtained from samples with no drug exposure that were processed simultaneously. Dose -response interactions between paclitaxel and 5-fluorouracil at the point of IC80 were evaluated by the isobologram (Steel and Peckham, 1979) . The IC80 was defined as the concentration of drug that produced 80% cell growth inhibition; 80% reduction of absorbance. We used IC80 instead of the more common IC50 as the combined effects at IC50 were sometimes different from those of IC80, which would be more important than ICso in this study. Figure 1 shows a schematic isobologram. The theoretical basis of the isobologram has been described previously (Steel and Peckham, 1979; Kano et al., 1988 Kano et al., , 1992 . Three isoeffect curves were constructed based upon the dose -response curves of paclitaxel and 5-fluorouracil.
Materials and methods
(1) Mode I line (solid line in Figure 1 ): When the dose of paclitaxel was chosen, an incremental effect remained to be produced by 5-fluorouracil. The addition was calculated by taking the increment in doses, starting from zero, that produced log survivals that added up to IC80 (heteroaddition). If the agents are acting additively by independent mechanism, combined data points would lie near the mode I line.
(2) Mode 11 (a) line (dotted line in Figure 1 ). When the dose of paclitaxel was chosen, an incremental effect remained to be produced by 5-fluorouracil. The addition was calculated by taking the increment in doses, starting from the point on the dose-response curve of paclitaxel where the effect of paclitaxel had ended, that produced log survivals that added up to IC80 (isoaddition).
(3) Mode 11 (b) line (dotted line in Figure 1 ). Similarly to procedure for the mode II (a) line, when the dose of 5-fluorouracil was chosen, an incremental effect remained to be produced by paclitaxel. The addition was calculated by taking the increment in doses, starting from the point on the doseresponse curve of 5-fluorouracil where its effect had ended, that produced log survivals that added up to IC80 (isoaddition). If the agents are acting additively by similar mechanism, combined data points would lie near mode II lines.
As we cannot know whether the combined effects of two agents will be heteroadditive, isoadditive or intermediate between these extremes, all possibilities should be considered. Thus, when the data points of the drug combination fell within the area surrounded by three lines (envelope of additivity) (Pb in Figure 1 ), the combination was regarded as additive. We used this envelope not only to evaluate simultaneous exposure to the paclitaxel and 5-fluorouracil combination, but also to evaluate the sequential exposure to both agents as the cytotoxicity of the first agent could be modulated by the second agent under our experimental conditions.
In this isobologram, an additive effect indicates great superiority of the combination to a single agent, even though the data points for the combination do not reach caused by higher doses of the two agents than predicted), but a) \ 10 within the square or on the line of the square (Pc in Figure 1 
Discussion
Paclitaxel is an important new drug with a novel mechanism of action and broad clinical activity. The optimal dose and schedule of paclitaxel, either as a single agent or in combination with other anti-cancer agents, has not yet been established (Arbuck, 1994) . The purpose of this study was to assess the cytotoxic interaction between paclitaxel and 5-fluorouracil, administered at various schedules, against four human cancer cell lines. The cytotoxic effect of the combination at IC80 was analysed by the isobologram method (Steel and Peckham, 1979) . Our studies clearly demonstrated that the cytotoxic interaction between paclitaxel and 5-fluorouracil was schedule dependent. Simultaneous exposure to these two agents for 24 h had slight antagonistic effects in three of the four human carcinoma cell lines examined. Sequential exposure to 5-fluorouracil for 24 h followed by paclitaxel for 24 h had antagonistic effects in all four cell lines, whereas sequential exposure to paclitaxel for 24 h followed by 5-fluorouracil for 24 h had additive effects in three of the four cell lines.
As combination schedules with antagonistic interaction are not generally employed, the short-term simultaneous administration of these two agents and the sequential administra-
tion of 5-fluorouracil followed by paclitaxel may be inappropriate in clinical use. In particular, the sequential administration of 5-fluorouracil followed by paclitaxel is not recommended as this sequence had mainly protective effects, suggesting that this combination would be no more effective than either single drug alone. The mechanisms of antagonistic interaction operating with these schedules are obscure. As cells are most sensitive against paclitaxel in M-phase (Lopes et al., 1993) , it is likely that 5-fluorouracil, which blocks cells in S-phase and prevents cells from entering M-phase, would be antagonistic with paclitaxel if both agents were exposed simultaneously or 5-fluorouracil precedes paclitaxel exposure. However, when cells are exposed to paclitaxel first, cells are blocked in G2/M. Paclitaxel is considered to reduce cytotoxicity due to 5-fluorouracil by preventing cells entering S-phase, in which cells are most sensitive to 5-fluorouracil. The latter speculation is not always consistent with our findings that sequential exposure to pacitaxel followed by 5-fluorouracil showed additive effects. The changes in the cell cycle transition may be insufficient to explain cytotoxic interaction between these agents. The study of 5-fluorouracil-induced alterations in cell cycle kinetics, uptake, and biochemical pharmacology of paclitaxel or vice versa, will be important to clarify the mechanism of additive or antagonistic interaction between two agents in various schedules.
Our findings suggest that the sequential administration of pacitaxel followed by 5-fluorouracil may be a suitable schedule in terms of cytotoxic effects. However, as paclitaxel and 5-fluorouracil exhibit a dose-limiting toxicity of granulocytopenia, the combination of these two agents may raise the usual oncological problem of the concomitant increase of both efficacy and myelotoxicity. The use of granulocyte colony-stimulating factor could eliminate the granulocytopenia, and, thus, prevent a reduction in the dose level of this combination. Although paclitaxel has been administered as 3 h and 24 h infusions (Arbuck, 1994) , its optimal schedule as a single agent has not yet been determined. In human cancer cell lines in culture, the cytotoxic effects of paclitaxel seemed to increase more with prolongation of exposure time than with increases in the concentration (Rowinsky et al., 1988; Lopes et al., 1993) . Longer drug exposure times partially overcome multidrug resistance, a mechanism that operates in a variety of cancers (Lai et al., 1991) . Some recent clinical trials of paclitaxel have shown that prolonged infusion schedules may be more effective than shorter schedules (Wilson et al., 1994) . 5-Fluorouracil has been administered by bolus infusion and by continuous long-term infusion. This drug exhibits different modes of action, depending on the administration schedule, the major mechanism of action of 5-fluorouracil in short-term exposure being considered to be the incorporation of fluorouridine triphosphate into RNA, and that operating in long-term exposure, the inhibition of thymidylate synthase by 5-fluoro-2'-deoxyuridylate (Aschele et al., 1992) . These findings suggest that the effects of simultaneous exposure to the combination of paclitaxel and 5-fluorouracil may vary depending on exposure time.
We, therefore, also studied the effects of the combination of these two agents in cells exposed simultaneously to both agents for 5 days. Interestingly, the simultaneous exposure to paclitaxel and 5-fluorouracil had additive effects in three of the four cell lines, although simultaneous exposure to these two agents for 24 h had antagonistic effects in three of the four cell lines. We also observed that simultaneous exposure to these two agents for 4 h had antagonistic effects in all cell lines (data not shown). These findings suggest that the prolonged simultaneous administration of paclitaxel and 5-fluorouracil may circumvent the antagonistic interaction seen with short-term simultaneous administration.
The pharmacokinetic interactions of paclitaxel and cisplatin and paclitaxel and doxorubicin have recently been studied (Rowinsky et al., 1991; Holmes et al., 1994) . Interestingly, the sequential administration of cisplatin followed by paclitaxel decreased paclitaxel clearance, resulting in higher toxicity than the reverse sequence. With the paclitaxel and doxorubicin combination, the sequential administration of paclitaxel followed by doxorubicin decreased doxorubicin clearance, resulting in higher toxicity than the reverse sequence. Clinical studies of the pharmacokinetic interactions and toxicities of paclitaxel administered with 5-fluorouracil may also be important in designing clinical regimens.
In conclusion, the present study showed that simultaneous exposure to paclitaxel and 5-fluorouracil and sequential exposure to 5-fluorouracil followed by paclitaxel had antagonistic effects, whereas sequential exposure to paclitaxel followed by 5-fluorouracil had additive effects. These findings suggest that the sequential administration of paclitaxel followed by 5-fluorouracil may be the optimal schedule for this combination. Long-term exposure to both agents had mainly additive effects, suggesting that the prolonged simultaneous administration of both agents may circumvent the antagonistic interaction that occurred with short-term simultaneous administration. Further preclinical and clinical investigations of this combination are required to better understand its anti-tumour, toxic and pharmacokinetic interactions.
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